Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Temporary Halts in Generic Product Marketing, JGA Accelerates Efforts in Collecting Information
November 19, 2012
- Average Foreign Price Adjustment Results in NHI Price Lower than Manufacturing Cost for Pfizer Japan’s Tygacil: CSIMC
November 16, 2012
- CSIMC Subcommittee Eyes Price Cuts for Long-Listed Drugs with Slow Generic Penetration
November 16, 2012
- CSIMC OKs Listing for 15 APIs/22 Products; Peak Sales Estimated at 32.6 Billion Yen for Lotriga
November 15, 2012
- MHLW Director Suggests Being Ready for Increased Official Management if 3rd Round of Distribution Reform Fails
November 14, 2012
- Health Coverage for OTC-Like Drugs Up for Review Yet Again
November 13, 2012
- Hodanren Asks MHLW to Disclose Discussions by Members of Drug Pricing Organization
November 13, 2012
- Zoledronic Acid, Sildenafil Subject to Pilot Study on Generic RMPs
November 12, 2012
- Drug Makers Invited to Join in Intractable Disease Drug Discovery Research Using iPS Cells from This Fiscal Year
November 8, 2012
- 15 Pharmacies Wrongly Claimed 41.6 Million Yen in Dispensing Fees Over 6 Year Period: Board of Audit
November 7, 2012
- Kampo Should Be Excluded from Denominator to Figure out Generic Volume Share
November 5, 2012
- CSIMC Expert Subcommittee Supports Continuation of Different NHI Prices for Long-Listed Drugs and Generics
November 2, 2012
- PAFSC’s 2nd Committee Recommends Additional Indication for Biosimilar Gran
November 2, 2012
- Number of Diseases Eligible for Medical Aid Would Increase to Over 300 Under New Proposal
November 1, 2012
- RMP to Be Made Available through the Internet During Review Stage: Director Tawaragi of PFSB
October 30, 2012
- MHLW Earmarks 200 Mil. Yen for Drug Quality Assurance and Development of New Vaccine Quality Test Methods as Part of Emergency Economic Measures
October 30, 2012
- Japan Adopts Emergency Economic Package, 3.8 Billion Yen Front-Loaded for iPS Research, Drug Discovery Support
October 30, 2012
- PAFSC’s 1st Committee Recommends Approval for Pfizer’s OAB Drug Toviaz
October 29, 2012
- DPJ Vice President Sengoku Says JMA “Paranoid” over TPP Concerns
October 29, 2012
- Keidanren, JCCI Call for Expansion of R&D Tax Break System at Tax Commission Hearings
October 29, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…